Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Adaptive Biotechnologies (Nasdaq: ADPT) will report first quarter 2026 financial results after market close on May 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report first quarter 2026 financial results after market close on May 5, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with archived replay available within 24 hours.
Investors can access live audio via the company’s Investors website.
Details
News Market Reaction – ADPT
On Apr 16, the first trading day after this news, ADPT closed 3.10% below the previous close.
Data tracked by StockTitan Argus for the Apr 16 session.
Key Figures
- Earnings date
- May 5, 2026
- Scheduled Q1 2026 financial results release after market close
- Conference call time PT
- 1:30 p.m. Pacific Time
- Start time for Q1 2026 webcast
- Conference call time ET
- 4:30 p.m. Eastern Time
- Start time for Q1 2026 webcast
- Webcast replay availability
- Within 24 hours
- Archive timing after Q1 2026 event
Previous Earnings date Reports
-
Set timing for Q4 and FY2025 results and investor webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.